Metformin ameliorates neuroinflammatory environment for neurons and astrocytes during in vitro and in vivo stroke and tobacco smoke chemical exposure: Role of Nrf2 activation

• Published in: Redox biology Vol. 75; p. 103266
• Main Authors: Akter, Khondker Ayesha, Sharma, Sejal, Sifat, Ali Ehsan, Zhang, Yong, Patel, Dhaval Kumar, Cucullo, Luca, Abbruscato, Thomas J.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-09-2024; Elsevier
• Subjects: Adolescent mice; Animals; Astrocytes - drug effects; Astrocytes - metabolism; Cytokines; Cytokines - metabolism; Disease Models, Animal; Humans; Ischemic stroke; Metformin - pharmacology; Mice; Neuroinflammation; Neuroinflammatory Diseases - drug therapy; Neuroinflammatory Diseases - etiology; Neuroinflammatory Diseases - metabolism; Neurons - drug effects; Neurons - metabolism; NF-E2-Related Factor 2 - metabolism; NF-kappa B - metabolism; Reactive Oxygen Species - metabolism; Research Paper; ROS; Signal Transduction - drug effects; Stroke - drug therapy; Stroke - metabolism; Tobacco smoke; Neuroinflammation; Tobacco smoke; Ischemic stroke; Cytokines; Adolescent mice; ROS
• ISSN: 2213-2317; 2213-2317
• DOI: 10.1016/j.redox.2024.103266

Despite the protective nature of the blood-brain barrier (BBB) and brain-protecting tissues, some types of CNS injury or stress can cause cerebral cytokine production and profound alterations in brain function. Neuroinflammation, which can also be accompanied by increased cerebral cytokine production, has a remarkable impact on the pathogenesis of many neurological illnesses, including loss of BBB integrity and ischemic stroke, yet effective treatment choices for these diseases are currently lacking. Although little is known about the brain effects of Metformin (MF), a commonly prescribed first-line antidiabetic drug, prior research suggested that it may be useful in preventing BBB deterioration and the increased risk of stroke caused by tobacco smoking (TS). Therefore, reducing neuroinflammation by escalating anti-inflammatory cytokine production and declining pro-inflammatory cytokine production could prove an effective therapeutic strategy for ischemic stroke. Hence, the current investigation was planned to explore the potential role of MF against stroke and TS-induced neuroinflammation and reactive oxygen species (ROS) production. Our studies revealed that MF suppressed releasing pro-inflammatory mediators like tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) by aiming at the nuclear factor kappa B (NF-κB) signaling pathway in primary neurons and astrocytes. MF also upregulated anti-inflammatory mediators, like interleukin-10 (IL-10), and interleukin-4 (IL-4), by upregulating the Nrf2-ARE signaling pathway. Adolescent mice receiving MF along with TS exposure also showed a notable decrease in NF-κB expression compared to the mice not treated with MF and significantly decreased the level of TNF-α, IL-1β, MCP-1, and MIP-2 and increased the levels of IL-10 and IL-4 through the activation of Nrf2-ARE signaling pathway. These results suggest that MF has anti-neuroinflammatory effects via inhibiting NF-κB signaling by activating Nrf2-ARE. These studies support that MF could be a strong candidate drug for treating and or preventing TS-induced neuroinflammation and ischemic stroke.